Minerva Neurosciences Aktie [Valor: 24230665 / ISIN: US6033801068]

Kaufen

Verkaufen

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen
			Ausblick

Kurse + Charts + Realtime
Kurs + Chart
Chart (gross)
Times + Sales
Chartvergleich
Börsenplätze
Realtime Push
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen
Ausblick

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Strukturierte Produkte

Nachrichten zu Minerva Neurosciences Inc

14.11.19	Minerva Neurosciences, Inc : Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019 (Investegate)
04.11.19	Minerva Neurosciences Inc (NERV) Q3 2019 Earnings Call Transcript (MotleyFool)
04.11.19	Minerva Neurosciences, Inc : Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates (Investegate)
28.10.19	Minerva Neurosciences, Inc : Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019 (Investegate)
01.10.19	Minerva Neurosciences Inc (NERV) Q3 2019 Earnings Call Transcript (MotleyFool)
01.10.19	Here's Why Minerva Neurosciences Fell Over 28% Today (MotleyFool)
01.10.19	Minerva Neurosciences, Inc : Minerva Neurosciences Announces Update for Three Clinical Trials (Investegate)
24.09.19	Minerva Neurosciences, Inc : Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone (Investegate)
05.08.19	Minerva Neurosciences, Inc. (NERV) Q2 2019 Earnings Call Transcript (MotleyFool)
05.08.19	Minerva Neurosciences, Inc : Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates (Investegate)
29.07.19	Minerva Neurosciences, Inc : Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019 (Investegate)
24.06.19	UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals (Market Watch)
24.06.19	Minerva Neurosciences, Inc : Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia (Investegate)
12.06.19	Minerva Neurosciences, Inc : Minerva Neurosciences to Present at JMP Securities Life Sciences Conference (Investegate)
29.05.19	Minerva Neurosciences, Inc : Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019 (Investegate)
18.03.19	Minerva Neurosciences, Inc : Minerva Neurosciences to Host Webcast Event on Schizophrenia (Investegate)
12.03.19	Minerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript (MotleyFool)
12.03.19	Minerva Neurosciences, Inc : Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates (Investegate)
05.03.19	Minerva Neurosciences, Inc : Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019 (Investegate)
28.11.18	Minerva Neurosciences, Inc : Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain (Investegate)
21.11.18	Minerva Neurosciences, Inc : Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018 (Investegate)
19.11.18	Minerva Neurosciences, Inc : Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers (Investegate)
15.11.18	Minerva Neurosciences, Inc : Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018 (Investegate)
05.11.18	Minerva Neurosciences, Inc : Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates (Investegate)
29.10.18	Minerva Neurosciences, Inc : Minerva Neurosciences to Report Third Quarter 2... (Investegate)
22.08.18	Minerva Neurosciences, Inc : Minerva Neurosciences Announces Findings Showin... (Investegate)
02.08.18	Minerva Neurosciences, Inc : Minerva Neurosciences Reports Second Quarter 20... (Investegate)
26.07.18	Minerva Neurosciences, Inc. : Minerva Neurosciences to Report Second Quarter ... (Investegate)
25.07.18	Minerva Neurosciences, Inc. : Minerva Neurosciences Names Devin Smith Senior ... (Investegate)
30.05.18	Minerva Neurosciences, Inc. : Minerva Neurosciences to Present at Jefferies 2... (Investegate)
17.05.18	Minerva Neurosciences shares rise 5% on trial results for schizophrenia drug (Market Watch)
17.05.18	Minerva Neurosciences, Inc. : Journal of Clinical Psychiatry Publishes Positi... (Investegate)
03.05.18	Minerva Neurosciences, Inc. : Minerva Neurosciences Reports First Quarter 201... (Investegate)
12.03.18	Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates (Benzinga)
06.11.17	Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates (Benzinga)
07.08.17	Why Minerva Neurosciences Inc. Fell 31.1% in July (MotleyFool)
03.08.17	Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates (Benzinga)
01.06.17	Why Minerva Neurosciences Stock Is Soaring Today (MotleyFool)
15.05.17	Minerva Neurosciences stock rises 7% on plans to advance schizophrenia drug to late-stage trials (Market Watch)
15.05.17	Minerva Neurosciences announces plans for Phase3 trial of schizophrenia treatment (MarketWatch)
04.05.17	Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates (Benzinga)
26.05.16	Mid-Afternoon Market Update: Abercrombie & Fitch Slides On Disappointing Results; Minerva Neurosciences Shares Spike Higher (Benzinga)
26.05.16	Minerva Neurosciences Shares Jump 200% On Positive Results From Phase IIB Study of MIN-101 Monotherapy (Benzinga)
05.01.15	Minerva Neurosciences shares rally on animal Parkinson's study (Market Watch)

Newssuche

CS Group

13.31

1.41 %

Long

Short

CieFinRichemont

76.30

1.33 %

Long

Short

UBS Group

12.20

1.04 %

Long

Short

LafargeHolcim

53.02

1.03 %

Long

Short

Zurich Insur Gr

397.60

0.89 %

Long

Short

Nestle

103.30

0.35 %

Long

Short

Geberit

541.40

0.30 %

Long

Short

The Swatch Grp

277.40

0.18 %

Long

Short

ABB

23.29

0.09 %

Long

Short

Novartis

90.97

-0.26 %

Long

Short

mehr

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
Valor / ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:
Kaufwert:	CHF
	Hinzufügen Speichern

Minerva Neurosciences Aktie [Valor: 24230665 / ISIN: US6033801068]

Nachrichten zu Minerva Neurosciences Inc

Eintrag hinzufügen Eintrag bearbeiten

Newssuche

Aktien Top Flop

Meistgelesene Nachrichten